- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| GUARD THERAPEUTICS INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
| 04.09.24 | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Guard Therapeutics International AB | 356 | GlobeNewswire | With effect from September 05, 2024, the subscription rights in Guard
Therapeutics International AB will be traded on First North Growth Market.
Trading will continue up until and including September... ► Artikel lesen | |
| 02.09.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.09.2024 | 481 | Xetra Newsboard | Das Instrument MSPA MA0000011488 ITISSALAT AL-MA. INH.DH 6 EQUITY wird cum Kapitalmassnahme gehandelt am 02.09.2024 und ex Kapitalmassnahme am 03.09.2024 The instrument MSPA MA0000011488 ITISSALAT AL-MA.... ► Artikel lesen | |
| 29.08.24 | Guard Therapeutics International AB: First patient dosed in Guard Therapeutics' phase 2b study POINTER | 181 | GlobeNewswire (Europe) | Guard Therapeutics today announced that the first patient has been dosed in the phase 2b clinical study POINTER with the drug candidate RMC-035 as a kidney-protective treatment in open-heart surgery.
"It... ► Artikel lesen | |
| 27.08.24 | Guard Therapeutics International AB: Guard Therapeutics carries out announced rights issue (repair issue) | 152 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, DISTRIBUTED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen |
4 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 53,64 | +0,41 % | Novonesis (Novozymes A/S): Change to the Executive Leadership Team | ||
| GENMAB | 214,70 | +0,09 % | Genmab A/S: EPKINLY (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma | Approval based on results from two Phase 1/2 EPCORE clinical trials, which demonstrated strong and durable efficacy in patients with relapsed or refractory (R/R) follicular lymphoma (FL) who... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,278 | +0,12 % | Arbutus Biopharma Aktie: Portfolioerweiterungen im Fokus | Die Arbutus Biopharma Corporation verzeichnete am 18. Januar 2025 eine leichte Abwärtsbewegung an der Börse. Der Aktienkurs des Biotech-Unternehmens sank um 0,62 Prozent auf 3,20 USD. Die Marktkapitalisierung... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,450 | 0,00 % | Pre-market Movers: Moleculin Biotech, Bellevue Life Sciences Acquisition, ScanTech AI Systems, Serve Robotics, Informatica | LONDON (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.25 A.M. ET).In the Green Moleculin Biotech, Inc. (MBRX) is up over 53% at $1.95.
ScanTech... ► Artikel lesen | |
| VERICEL | 50,000 | +0,40 % | Vericel Corporation: Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets | Full-Year 2024 Total Revenue Growth of 20% and Adjusted EBITDA Growth of Approximately 55% MACI Full-Year 2024 Revenue Growth of 20%, with Fourth Quarter Revenue of $68.2 to $68.7 Million Highest... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 0,455 | +4,60 % | Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones | - Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update expected in Q2 2025 - BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 2,950 | 0,00 % | BTAI-Aktie fällt auf 52-Wochen-Tief von 2,16 US-Dollar | ||
| MUSTGROW BIOLOGICS | 0,846 | 0,00 % | MustGrow Biologics Corp.: MustGrow Signs Exclusive Distribution Agreement with Adjuvants Plus Inc. for Biological Product Line | Saskatoon, Saskatchewan--(Newsfile Corp. - February 11, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), a leading provider of biological and regenerative... ► Artikel lesen | |
| REGENXBIO | 6,850 | -1,44 % | Regenxbio Aktie: Wolf im Schafspelz? | Der Biotechnologiekonzern Regenxbio verzeichnet aktuell eine herausfordernde Marktphase. Die Aktie des Unternehmens, das sich auf Gentherapie-Produktkandidaten spezialisiert hat, notiert derzeit bei... ► Artikel lesen | |
| AKEBIA | 1,729 | +0,41 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 6,500 | +2,36 % | Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI In Germany | ~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to ~ Norgine Pharmaceuticals'... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 7,600 | +4,11 % | KemPharm Aktie: Klarer Anstieg im Berichtszeitraum | Die Aktie des Pharmaunternehmens Zevra Therapeutics verzeichnet derzeit eine bemerkenswerte Entwicklung an der NASDAQ. Während der Kurs in der Nähe von 8,07 US-Dollar notiert und im vergangenen Jahr... ► Artikel lesen | |
| REVANCE THERAPEUTICS | 3,420 | 0,00 % | Revance Therapeutics, Inc. - 15-12G, Securities registration termination | ||
| CORVUS PHARMACEUTICALS | 4,045 | +1,12 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis | BURLINGAME, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 18,000 | 0,00 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants | FREDERICK, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment... ► Artikel lesen |
GUARD THERAPEUTICS INTERNATIONAL AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,040 (+2,45 %) liegt der Kurs bei 1,670 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GUARD THERAPEUTICS INTERNATIONAL AB finden Sie auf Wallstreet Online.
